Nuvation Bio Inc.
NYSE:NUVBBiotechnology
+$0.06 today
- Market cap
- $1.33B
- Beta
- 1.56
- P/E (TTM)
- -12.8
- EPS (TTM)
- -$0.42
Volume 5.96M
Average 4.07M
NUVB Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Nuvation Bio Inc.NYSE: NUVB
Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026
Depreciation & amortization turns negative
Q2 FY2026 depreciation & amortization was -$536K, compared with $356K a year earlier. Trailing-twelve-month depreciation & amortization was -$666K. Over 3 fiscal years it compounded at +106.0% a year.
Context
- Depreciation & amortization amounted to 2.8% of revenue in FY2025, down 5.9 pp from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly depreciation & amortization holds near -$536K or moves back toward the trailing-twelve-month quarterly average of -$166.5K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 1.74M USD
- Year-over-year change
- +154.6%
- 4-year CAGR
- +75.3%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.74M | +154.6% |
| FY2024 | 2024-12-31 | 683K | +207.7% |
| FY2023 | 2023-12-31 | 222K | +11.6% |
| FY2022 | 2022-12-31 | 199K | +8.2% |
| FY2021 | 2021-12-31 | 184K | — |
Depreciation & Amortization vs competitors
How NUVB compares with its peers on the latest reported figures
- NUVB's LTM Jun 2026 depreciation & amortization of $666K is the 9th largest of the 11 companies compared; the peer median is $3.1M.
- Its year-over-year change of -163.6% is the lowest of 11, against a peer median of +0.4%.
- Depreciation & amortization amounts to 0.4% of revenue for NUVB, versus a peer median of 9.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $32.16M | -7.6% | -4.5% | 47.4% | |
| LTM Jun 2026 | $19.38M | -0.5% | +50.7% | 6.2% | |
| LTM Mar 2026 | $5.93M | -59.2% | +20.0% | 32.8% | |
| LTM Mar 2026 | $4.63M | +20.2% | +27.0% | 8.9% | |
| LTM Sep 2026 | $3.73M | +10.4% | +5.3% | 3333.9% | |
| LTM Jun 2026 | $2.47M | +124.0% | +68.8% | — | |
| LTM Sep 2026 | $2.35M | +1.4% | +61.5% | — | |
| LTM Mar 2026 | $1.98M | -3.3% | +34.1% | 9.2% | |
| LTM Jun 2026 | $666K | -163.6% | +106.0% | 0.4% | |
| LTM Jun 2026 | $652K | +130.4% | — | — | |
| LTM Jun 2026 | $468K | -3.1% | +21.7% | 0.7% | |
| Peer median (excluding NUVB) | $3.1M | +0.4% | +27.0% | 9.2% | |
Competitors are the stored peer set for NUVB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (86.85M) | (104.2M) | (75.8M) | (567.94M) | (204.63M) |
| Depreciation & Amortization | 184K | 199K | 222K | 683K | 1.74M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 9.27M | 16.29M | 19.51M | 32.28M | 35.89M |
| Change in Working Capital | 4.79M | (3.45M) | 540K | (12.51M) | (11.98M) |
| Accounts Receivables | (1.95M) | 554K | (1.22M) | (12.59M) | (3.07M) |
| Inventory | 0 | 0 | 0 | 0 | (11.41M) |
| Accounts Payables | 1.86M | (1.79M) | 70K | (1.65M) | 3.13M |
| Other Working Capital | 4.88M | (2.22M) | 1.69M | 1.74M | (630K) |
| Other Non-Cash Items | 4.41M | (4.95M) | (12.47M) | 417.08M | 5.55M |
| Operating Cash Flow | (68.19M) | (96.11M) | (68M) | (130.41M) | (173.43M) |
| Capital Expenditures | (282K) | (370K) | (69K) | (162K) | (354K) |
| Acquisitions (Net) | 0 | 0 | 0 | 12.43M | 0 |
| Purchases of Investments | (609.3M) | (520.31M) | (703.37M) | (339.65M) | (354.42M) |
| Sales of Investments | 154.91M | 584.12M | 712.35M | 450.08M | 462.29M |
| Other Investing Activities | 0 | 13K | 14K | 0 | 0 |
| Investing Cash Flow | (454.67M) | 63.46M | 8.92M | 122.7M | 99.52M |
| Debt Repayment | 0 | 0 | 0 | (4.55M) | 191.11M |
| Common Stock Issued | 0 | 0 | 0 | 4.89M | 11.42M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 625.53M | 1.33M | 628K | 0 | 0 |
| Financing Cash Flow | 625.53M | 1.33M | 628K | 331K | 202.54M |
| Effect of Forex Changes | 0 | 0 | 0 | 453K | (265K) |
| Net Change in Cash | 102.67M | (31.32M) | (58.45M) | (6.93M) | 128.36M |
| Free Cash Flow | (68.47M) | (96.48M) | (68.07M) | (130.58M) | (173.78M) |
Nuvation Bio Inc.
NYSE:NUVB
Intrinsic Alpha fair value
Locked
Current Price
$3.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.